Talphera (TLPH) Competitors $0.49 +0.01 (+1.21%) Closing price 04:00 PM EasternExtended Trading$0.48 -0.01 (-2.78%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLPH vs. ITRM, SCYX, CLSD, RANI, EQ, AKTX, ALXO, ESLA, TPST, and CLNNShould you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), Clearside Biomedical (CLSD), Rani Therapeutics (RANI), Equillium (EQ), Akari Therapeutics (AKTX), ALX Oncology (ALXO), Estrella Immunopharma (ESLA), Tempest Therapeutics (TPST), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry. Talphera vs. Its Competitors Iterum Therapeutics SCYNEXIS Clearside Biomedical Rani Therapeutics Equillium Akari Therapeutics ALX Oncology Estrella Immunopharma Tempest Therapeutics Clene Talphera (NASDAQ:TLPH) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment. Do analysts rate TLPH or ITRM? Talphera presently has a consensus price target of $5.00, indicating a potential upside of 914.82%. Iterum Therapeutics has a consensus price target of $9.00, indicating a potential upside of 1,109.68%. Given Iterum Therapeutics' higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than Talphera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to TLPH or ITRM? In the previous week, Iterum Therapeutics had 1 more articles in the media than Talphera. MarketBeat recorded 3 mentions for Iterum Therapeutics and 2 mentions for Talphera. Talphera's average media sentiment score of 0.20 beat Iterum Therapeutics' score of 0.00 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iterum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in TLPH or ITRM? 37.7% of Talphera shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 3.2% of Talphera shares are owned by company insiders. Comparatively, 2.4% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is TLPH or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat Talphera's return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -152.38% -64.32% Iterum Therapeutics N/A N/A -65.01% Which has more risk & volatility, TLPH or ITRM? Talphera has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.85, suggesting that its share price is 185% more volatile than the S&P 500. Which has preferable earnings & valuation, TLPH or ITRM? Talphera has higher revenue and earnings than Iterum Therapeutics. Talphera is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$650K15.55-$13M-$0.40-1.23Iterum TherapeuticsN/AN/A-$24.77M-$0.85-0.88 SummaryTalphera beats Iterum Therapeutics on 10 of the 15 factors compared between the two stocks. Get Talphera News Delivered to You Automatically Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLPH vs. The Competition Export to ExcelMetricTalpheraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.99M$2.51B$5.76B$9.59BDividend YieldN/A1.67%4.41%4.09%P/E Ratio-1.2322.6131.1026.05Price / Sales15.55747.15470.24120.75Price / CashN/A180.4637.7358.48Price / Book1.545.939.536.61Net Income-$13M$31.83M$3.26B$265.56M7 Day Performance15.85%1.80%2.11%1.98%1 Month Performance23.18%4.36%5.12%1.33%1 Year Performance-45.26%11.44%31.25%21.15% Talphera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLPHTalphera2.9046 of 5 stars$0.49+1.2%$5.00+914.8%-46.6%$9.99M$650K-1.2319Gap DownITRMIterum Therapeutics1.917 of 5 stars$0.77+8.4%$9.00+1,062.8%-42.3%$33.72MN/A-0.8910SCYXSCYNEXIS1.0345 of 5 stars$0.86-2.8%N/A-54.3%$33.36M$3.75M-1.5360News CoverageAnalyst RevisionCLSDClearside Biomedical2.0889 of 5 stars$0.42+5.2%$4.20+890.6%-60.1%$33.29M$1.66M-1.1530RANIRani Therapeutics2.7193 of 5 stars$0.53+5.0%$7.33+1,296.8%-81.1%$33.19M$1.03M-0.58110EQEquillium0.9841 of 5 stars$0.94+5.8%$3.00+220.2%+89.6%$33.15M$41.10M-2.3840Gap DownHigh Trading VolumeAKTXAkari Therapeutics2.4143 of 5 stars$1.03-2.4%$5.00+387.8%-74.2%$32.98MN/A0.009ALXOALX Oncology3.1056 of 5 stars$0.61-0.1%$3.30+437.5%-58.8%$32.79MN/A-0.2540Analyst RevisionESLAEstrella Immunopharma2.3417 of 5 stars$0.87+0.6%$16.00+1,739.1%-37.6%$31.47MN/A-3.35N/ATPSTTempest Therapeutics1.2391 of 5 stars$8.50+6.1%$30.00+252.9%-51.4%$31.28MN/A-0.4720CLNNClene3.271 of 5 stars$3.76-1.5%$40.00+963.5%+3.5%$31.10M$340K-0.93100Analyst Forecast Related Companies and Tools Related Companies Iterum Therapeutics Alternatives SCYNEXIS Alternatives Clearside Biomedical Alternatives Rani Therapeutics Alternatives Equillium Alternatives Akari Therapeutics Alternatives ALX Oncology Alternatives Estrella Immunopharma Alternatives Tempest Therapeutics Alternatives Clene Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLPH) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access